Floatz logo

Bms-214662

Unspecified Childhood Solid Tumor, Protocol Specific

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Unspecified Childhood Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2/3BBB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
Carboplatin
Seoul National University Hospital
Phase 2/3BBB
Evomela
City of Hope Medical Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Bms-214662 is also rated in:

cancer of unknown primary siteDormant
B
Indicative ·
58 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
47 / 100
View asset →
myelodysplastic syndrome with excess blastsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →